Meet CRI’s New CEO Alicia Zhou, PhD
Give today for a world immune to cancer tomorrow.
Donations up to $100,000 will be matched by a generous board member only until December 31, 2024.
Your Support & How It Was Used
FISCAL YEAR 2024 IMPACT REPORT (JULY 1, 2023 – JUNE 30, 2024)
in total scientific research funding
cancers now treatable with immunotherapy
of newly diagnosed patients eligible for immunotherapy
of total expenses support research and education
For a World Immune to Cancer
We established immunotherapy as the fourth pillar in treating cancer for one reason only – to save more lives.
Inventing the Next Wave in Immunotherapy
Breakthrough science has given researchers, clinicians, and patients new hope in the fight against cancer. With recent discoveries in immunotherapy treatments and an increased understanding of the immune system’s role in fighting disease, we are closer than ever before to transforming all cancers into curable diseases.
4M+ PATIENTS
$540m+ invested, the best minds.
Supporting and training scientists today for breakthrough discoveries in immunotherapy. We fund both open-ended laboratory research and data-driven clinical studies and turn discoveries into real-world results that save lives.
Promoting the Power of Our Immune System
CRI funds scientists from around the world to advance new avenues of discovery, new technologies, and new ways to analyze and share data about our immune system and its power to outsmart cancer — with the shared goal of making immunotherapy a lifesaving treatment for all cancers.
The IO Research Intelligence Center
As the science of cancer immunotherapy advances and the amount of data generated in clinical and laboratory studies grows exponentially, CRI is harnessing this information and putting it into the hands of our global community of research scientists to help speed the discovery and development of cancer cures.
Data on its own is not enough. We need to make sense of data within what we already know about cancer immunology. We need to marry data science, bioinformatics, and cancer immunology if we are going to take the next big leap of developing immunotherapies that are effective for all cancers.
Take Action
Make a gift today to make an impact now. Memorial and Honor donations also welcome. Your tax-deductible gift will fuel the discovery and development of powerful immunotherapies for all cancers.
Other Ways to Support CRI
We offer many convenient ways to support our mission. Be a fundraiser. Make a planned gift. Donate a vehicle. Explore all the many ways you can join in our lifesaving work.
Conquering Cancer Together
We cultivate lasting strategic partnerships with research institutions, cancer treatment centers, biopharmaceutical companies, and nonprofits to facilitate innovation in immuno-oncology and advance new lifesaving immunotherapies for more patients.
Annual Reports
CRI’s annual reports recount our accomplishments in the previous fiscal year.
Charity Ratings & Reporting
The Cancer Research Institute is a top-rated nonprofit organization.
Stay current on the latest cancer immunotherapy and CRI developments.
Browse CRI press releases, news articles, and subject matter experts.
Patient Summits
Patient Summits connect cancer patients with scientific and medical experts.
View immunotherapy webinars and how CRI’s work is impacting cancer research.
Bring to Life More Cures, Together
Become part of CRI’s mission to create a world immune to cancer
This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy .
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
- View all journals
- Explore content
- About the journal
- Publish with us
- Sign up for alerts
Multiomic analysis of familial adenomatous polyposis reveals molecular pathways associated with early tumorigenesis
- Edward D. Esplin
- Casey Hanson
- Michael P. Snyder
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas
Wu et al. perform single-cell analyses to explore the switch from low-grade to high-grade isocitrate-dehydrogenase-mutant glioma and show that it is characterized by oligodendrocyte progenitor cell-like cells transitioning to proliferative neural progenitor cell-like cells.
- L. Nicolas Gonzalez Castro
- Bradley E. Bernstein
γδ T cells as critical anti-tumor immune effectors
Fong and colleagues provide a Review on γδ T cells as mediators of anti-tumor immunity, discuss their role in the tumor microenvironment and reflect on therapeutic approaches to exploit γδ T cells.
- Marcel Arias-Badia
- Lawrence Fong
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export
Tripathi et al. identify a noncanonical RAS•GTP activity that increases XPO1-dependent export of nuclear proteins into the cytoplasm. This depends on a RAS–RanGAP1 complex, and this export function contributes to RAS oncogenic activity.
- Brajendra K. Tripathi
- Nicole H. Hirsh
- Douglas R. Lowy
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer
Yang et al. show that transcription–replication collisions lead to large tandem duplications, which are frequent in female-enriched, upper gastrointestinal tract and prostate cancers and are associated with poor survival and mutations in specific genes, such as CDK12 .
- Michelle L. Badura
- Lixing Yang
Current issue
Leveraging the potential for deintensification in cancer care.
- Jennifer A. Soon
- Fanny Franchini
- Grant A. McArthur
A 3D genome view of colon cancer initiation
- Adi Danieli-Mackay
- Argyris Papantonis
Phase separation rewires chromatin in breast cancer
- Rosaria Benedetti
- Lucia Altucci
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms
- Gianpietro Dotti
Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer
The neuroendocrine transition in prostate cancer is dynamic and dependent on ascl1.
- Rodrigo Romero
- Charles L. Sawyers
Announcements
Register now: The Human Tumor Atlas Network webinar
Join our live webinar on "The Human Tumor Atlas Network (HTAN): exploring tumor evolution in time and space". Drs Li Ding, Shannon Hughes and Ken Lau will discuss this exciting project with our Chief Editor Alexia-Ileana Zaromytidou. Register for Tuesday 14 January 2025 8:00 PST | 11:00 EST | 16:00 GMT | 17:00 CET
Nature Cancer Webcasts
View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.
Nature Cancer is a Transformative Journal ; authors can publish using the traditional publishing route OR via immediate gold Open Access.
Our Open Access option complies with funder and institutional requirements .
Advertisement
Latest Research articles
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression
Lyden and colleagues find that immune developmental genes, such as apoptotic peptidase activating factor 1 ( APAF1 ), support DNA packaging on the surface of tumor-derived extracellular vesicles that are taken up by resident liver macrophages, thereby suppressing metastasis.
- Inbal Wortzel
- David Lyden
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia
Tan and colleagues conducted a single-cell multiomic analysis of T cell acute lymphoblastic leukemia and identified a treatment-resistant subpopulation of bone marrow progenitor-like blasts associated with poor outcomes.
- Changya Chen
- David T. Teachey
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity
Yu and colleagues present a single-cell transcriptomic landscape of olfactory neuroblastoma, characterizing different tumor subtypes and cancer cell responses to drug treatments.
- Jingyi Yang
- Xiaole Song
- Hongmeng Yu
Latest Reviews & Analysis
Anti-metastatic extracellular vesicles carrying DNA
Cancer cells often secrete extracellular vesicles (EVs), bubble-like structures thought to elicit pro-metastatic states. New work shows that colorectal cancers systemically export their genetic material attached to the surface of specific EVs. These DNA-carrying EVs are taken up by macrophages in the liver, activating anti-metastatic immune responses.
Bone marrow progenitor-like cells against leukemia cure
Relapse in T cell acute lymphoblastic leukemia (T-ALL) constitutes a challenge. A subclonal population of bone marrow progenitor-like cells present in all T-ALL genetic or immunophenotypic subtypes is now shown to confer chemoresistance and poor prognosis, and to be targetable with anti-apoptotic agents.
- Sarah Elitzur
- Shai Izraeli
Modeling adenoma–carcinoma progression from a single MLH1 -knockout cell via colon organoids
Starting from a single MLH1- knockout human colon cell, we modeled the transition of daughter cells and resultant organoids from normal epithelium to carcinoma by sequentially selecting cells with spontaneously acquired mutations. The mutations were those common in patients who have Lynch syndrome-associated colorectal cancer with high microsatellite instability, and induced insensitivity to growth factors that restrict the growth of adult stem cells.
Defining the transcriptional lineages of breast cancer subtypes
In this work, we demonstrate the transcriptional networks that link breast cancer subtypes and their cells of origin, and how transcriptional signatures differ between benign cells and cancer.
The early molecular events driving cancer initiation remain elusive, hampering prognostic accuracy. A comparative analysis of 3D genomics data from all stages of colon malignant transformation now reveals that altered connectivity of gene promoters with cognate enhancers is both predictive of and rate-limiting in neoplasia.
Co-targeting metabolism and epigenetics in MDS with telaglenastat and azacytidine
Deciphering the response to bcma car t cell therapy.
- Hamza Hassan
- Marco L. Davila
Targeting therapy-persistent residual disease
- Xiaoxiao Sun
- Aaron N. Hata
News & Comment
Evidence-based reductions in cancer treatment that still preserve outcomes can result in an improved quality of life for patients and optimized healthcare resourcing. Using melanoma as an example, we define treatment deintensification, outlining barriers to its implementation, as well as existing guidance.
Quantum computing for oncology
As quantum technology advances, it holds immense potential to accelerate oncology discovery through enhanced molecular modeling, genomic analysis, medical imaging, and quantum sensing.
- Siddhi Ramesh
- Teague Tomesh
- Alexander T. Pearson
Connie Eaves (1944–2024)
- Gerry Krystal
- Xiaoyan Jiang
Trans-Atlantic twists and turns
Johanna Joyce received her PhD from the University of Cambridge, and did postdoctoral research at the University of California, San Francisco. She then joined the faculty at Memorial Sloan Kettering Cancer Center, New York, becoming a tenured member in 2014. She moved to Switzerland in 2016, where she later served as the inaugural executive director of the Agora Cancer Center Lausanne. She is currently a member of the Ludwig Institute for Cancer Research and a professor at the University of Lausanne.
- Johanna A. Joyce
Roadmap for a European cancer data management and precision medicine infrastructure
Gold-standard cancer data management is pivotal to enable precision medicine for European citizens. Achieving this goal relies on key elements: adopting standardized data formats, ensuring robust data privacy, educating professionals about the infrastructure’s benefits and leveraging cutting-edge technologies to transform cancer care.
- Macha Nikolski
- Eivind Hovig
- Gary Saunders
Lessons from withdrawn accelerated approvals in oncology
Drug regulatory agencies in the USA and Europe have mechanisms to provide patients faster access to novel treatments, expecting that follow-up trials will confirm clinically meaningful results. However, some early approvals are subsequently withdrawn. Here we discuss the insights gained from withdrawn accelerated approvals for oncologic agents in the past decade.
- George S. Mellgard
- Susan E. Bates
Trending - Altmetric
Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties
Science jobs
Chief editor, nature synthesis.
Job Title: Chief Editor, Nature Synthesis Location: New York, Shanghai or Beijing Closing date: Dec 31, 2024 About Springer Nature Group Springe...
New York City, New York (US)
Springer Nature Ltd
Endowed Chair and Institute Scientist in Molecular Imaging
Endowed Research Chair in Molecular Imaging within the most integrated academic hospital-based Molecular Imaging and Theranostics program in Canada.
London, Ontario (Canada)
St. Joseph's Health Care London
Technician/Senior Technician in Structural Proteomics
Job description APPLICATION CLOSING DATE: 18 January 2025 About the Institute Human Technopole (HT) is an interdisciplinary life science research...
Human Technopole
11 PhD positions
The joint DFG RTG 2887 “VISION” invites applications for PhD positions at the interface between structural biology, biomedicine and virology.
Luebeck / Hamburg (Northern Germany)
Universität zu Lübeck
Bioinformatician, Neurogenomics Research Center
APPLICATION CLOSING DATE: December 31th, 2024 Human Technopole (HT) is an interdisciplinary life science research institute, created and supported ...
Quick links
- Explore articles by subject
- Guide to authors
- Editorial policies
Improving the lives of all people through cancer research
For people affected by cancer.
NCI is the nation’s trusted source for cancer information. We are here for you with information about causes and risk factors, symptoms, how cancer is diagnosed, and treatment options.
- Find a Cancer Type
- Side Effects
- Causes & Prevention
- Diagnosis & Staging
- Find a Clinical Trial
For Researchers
Support for the best science underpins everything NCI does. Explore our resources to help researchers conduct their work and apply for funding and training opportunities.
- Funding Opportunities
- Resources for Researchers
- Apply for a Grant
- Training at NCI
- Find a Research Contact
- Key NCI Initiatives
Featured News and Research
The radiation option, which requires fewer sessions, compared well with other standard radiation approaches.
A small study may help explain why some Black people are hesitant to enroll in clinical trials.
Adding the immunotherapy drug nivolumab to chemo was more effective than the current standard treatment.
National Cancer Plan: Eliminate Inequities
Everyone needs equitable access to cancer care.
NCI Fiscal Year 2026 Annual Plan & Professional Judgment Budget Proposal
Each year, NCI prepares a plan for advancing cancer research and proposes the budget required to fund a broad research portfolio.
Get Answers
Connect with a cancer information specialist at 1-800-4-CANCER, through live chat, or by email.
Our Organization
Information about NCI Director Dr. W. Kimryn Rathmell and other senior NCI leaders.
NCI has 30 divisions, offices, and centers who work together to build, maintain, and enhance a cohesive and comprehensive cancer research agenda.
NCI relies on advisory committees to provide advice on the National Cancer Program, NCI scientific priorities, and more.
Genetics and Cancer Treatment
Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.
Home > Cancer Researchers / Other Health Care Professionals > Research
- AACR Cancer Centers Alliance
- News and Updates
- AACR Project GENIE: Biopharma Collaborative
- AACR Project GENIE®: Participation
- AACR Project GENIE®: Governance
- AACR Project GENIE: Data
- AACR Project GENIE®: Participating Individuals
- AACR Project GENIE®: Publications
- AACR Project GENIE: Support
- AACR Project GENIE: Frequently Asked Questions
- Understanding the COVID-19 Pandemic
- Cancer Researchers Working to Combat the COVID-19 Pandemic
- Future of Cancer Science and Medicine Beyond COVID-19
- Policies to Combat the Impact of a Global Health Crisis on Cancer Science and Medicine
- The AACR Call to Action
- A Snapshot of the Impact of the COVID-19 Pandemic on Cancer Research and Patient Care
- Awards and Lectureships
- Scientific Achievement Award Recipients
- AACR Distinguished Public Service Award Recipients
- AACR June L. Biedler Prize for Cancer Journalism Recipients
Fellows of the AACR Academy
- Scientific Review Committees
- Scientific Task Forces
- Scientific Working Groups
- Meetings and Workshops Calendar
Research Funding
AACR Project GENIE is a publicly accessible international cancer registry of real-world data assembled through data sharing.
Supporting the Complete Life Cycle of Research
As part of its mission to prevent and cure cancer, the American Association for Cancer Research fosters cancer and related biomedical science. By training emerging scientists; by creating communities around key disciplines; by funding promising projects; by convening thought leaders to overcome barriers to progress; by recognizing and celebrating key contributors to the field; and by collaborating with organizations around the world, the AACR supports the complete life cycle of cancer research.
The AACR Academy was established in 2013 to recognize and honor distinguished scientists whose major contributions have propelled significant innovation and progress against cancer. These Fellows of the AACR Academy have been selected through a rigorous peer review process that evaluates individuals on the basis of their stellar scientific achievements in cancer research or cancer-related biomedical science.
Scientific Achievement Awards and Lectureships
Since 1961, the AACR has presented hundreds of prizes, awards, and lectureships recognizing the achievements of researchers and physician-scientists who have made significant contributions to the understanding, diagnosis, prevention, and treatment of cancer.
Meetings, Educational Workshops, and Special Courses
Collaboration and communication are the foundation of scientific inquiry, and these elements are at the heart of the AACR’s scientific meetings . With larger conferences that drive innovation in critical areas of the field to smaller meetings focused on emerging areas and specific disease sites, the AACR provides forums for dynamic interactions and exciting science. The AACR Annual Meeting is the largest of its kind in the world for cancer researchers.
AACR Educational Workshops and Special Courses provide early-career investigators with opportunities to develop skills in clinical trial design, molecular biology, drug development, translational research, and related fields. These programs enable individuals with some career experience to sharpen their skills, expand their expertise, and form collaborations among peers and leaders from around the world.
Publications
The AACR publishes a portfolio of highly rated peer-reviewed journals that are among the most influential in cancer science and medicine. The entire portfolio of AACR journals, which represent just over 2 percent of the 313 journals in the oncology category, garnered about 13 percent of all citations in the same category, according to Journal Citation Reports TM from Clarivate, 2021. One half of the AACR journals rank in the top 8 percent in regard to impact factor in the oncology category. The latest addition to the AACR journal portfolio is Cancer Research Communications , an open access journal covering the full breadth of the field.
- Blood Cancer Discovery
- Cancer Discovery
- Cancer Epidemiology, Biomarkers & Prevention
- Cancer Immunology Research
- Cancer Prevention Research
- Cancer Research
- Cancer Research Communications
- Clinical Cancer Research
- Molecular Cancer Research
- Molecular Cancer Therapeutics
The AACR funds research directly, as well as in cooperation with numerous cancer-focused organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer-reviewed grant administration and scientific oversight of team science and individual grants for cancer research projects that have the potential to improve patient outcomes.
Scientific Task Forces, Committees, and Working Groups
In addition to supporting the cancer research agenda, the AACR helps to define it by convening thought leaders in key disciplines. AACR committees identify scientific priorities in critical research areas, and AACR task forces address challenges and explore important questions to drive innovation in the field.
Recognizing the vital need for communication and collaboration, the AACR also establishes working groups around selected scientific disciplines. These communities provide a forum for diverse groups of scientists who share a common interest to exchange knowledge and forge working relationships that accelerate progress against cancer.
- Cancer Evolution Working Group
- Cancer Immunology Working Group
- Cancer Prevention Working Group
- Chemistry in Cancer Research Working Group
- Hematologic Malignancies Working Group
- Pediatric Cancer Working Group
- Population Sciences Working Group
- Radiation Science and Medicine Working Group
- Tumor Microenvironment Working Group
- About the AACR
- New Open Access Journal, Cancer Research...
- Publish the Full Spectrum of Cancer Research
IMAGES